

Special Issue

Breakthrough in Imaging-Guided Precision Medicine in Neurology

Message from the Guest Editor

This Special Issue has a broad research scope on the application of neuroimaging and the variety of different central nervous disorders. You are invited to submit research and review articles related to the following potential topics or any research communications in conjunction with acute or chronic neuroinflammation:

- Neuroimaging of tau, amyloid-beta, and alpha-synuclein aggregation in the central nervous system
- Novel PET biomarkers for imaging brain damage, neuroinflammation, and disease progression of Alzheimer's disease, Lewy body diseases (Parkinson's disease, dementia with Lewy bodies, and Parkinson's disease dementia), epilepsy, and other central nervous system disorders
- Neuroimaging and its application in the evaluation of interventions targeting neuroinflammation
- Multiple imaging modalities of neuroinflammation
- Animal models and their application for neuroimaging
- Epigenetics for validation of neuroimaging biomarkers
- Longitudinal and cross-sectional imaging analyses
- Imaging interactions of astrocytes/microglia with neurons
- ...

We expect your submissions and look forward to working with you on publishing your research work.

Guest Editor

Dr. Jinbin Xu

Department of Radiology, Washington University School of Medicine,
St. Louis, MO 63110, USA

Deadline for manuscript submissions

closed (25 April 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/si/92881

*Journal of Personalized
Medicine*
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

Impact Factor 3.0
CiteScore 4.1
Indexed in PubMed



mdpi.com/journal/

jpm



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. David Alan Rizzieri

1. Novant Health Cancer Institute, Winston-Salem, NC 27103, USA

2. Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC 27710, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, and other databases.

Journal Rank:

JCR - Q1 (Medicine, General and Internal) / CiteScore - Q2 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 16.7 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2024).